A Phase 2 interventional study of BMS-986165 and Placebo in Ulcerative Colitis, sponsored by Bristol-Myers Squibb. Completed at 107 sites in 13 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-06.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb — 4 open to participants now, 5 under way, 1 of them phase 3. Colitis, Ulcerative · Bristol-Myers Squibb.
Among the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2019, is one of 7 in phase 2, and was the 12th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →4 of the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States
Women only
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
Bristol-Myers Squibb · Sites in United States, Australia, Belgium and 10 more countries
Ages 2–17
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 6 · Phase 4 1
First in 2006; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 131 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 131 across the 17 interventional studies, 1,182 across the 5 observational. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Colitis, Ulcerative by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07271069Bristol-Myers SquibbEffectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of oral deucravacitinib in participants with moderate to severe ulcerative colitis (UC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Drug: BMS-986165
Other: Placebo
Specified Dose on Specified Days
Also known as: Deucravacitinib
Specified Dose on Specified Days
Clinical Remission Response Rate at Week 12
Clinical remission response rate is the percentage of participants achieving clinical remission, defined as absolute total Mayo Score and absolute Mayo endoscopy, stool frequency, rectal bleeding. Will be calculated using a modified Mayo score with the following: Stool Frequency (SF) sub score ≤ 1, with ≥ 1 point decrease from baseline, and Rectal Bleeding (RB) sub score = 0, and Endoscopic (ES) sub score ≤ 1 (modified, excludes friability) The modified Mayo score (0 to 9 points) is the sum of 3 components: the SF, RB, and ES sub scores Modified Mayo Score: The modified Mayo score is a 9-point scale; a score of 5 to 9 points (inclusive), which is required for randomization, denotes moderate to severe disease (by protocol definition). considered in clinical remission if a Mayo Score of less than or equal to 2 with no individual sub score greater than 1
Time frame: From first dose to 12 weeks.
Clinical Response Rate at 12 Weeks
Clinical response is defined as percentage of participants with a reduction in total Mayo Score and reduction in rectal bleeding subscore Will be defined as the following: A decrease from baseline in the modified Mayo score of ≥ 2 points, and A decrease from baseline in the modified Mayo score ≥ 30%, and A decrease in rectal bleeding(RB) subscore of ≥ 1 point or absolute RB subscore ≤ 1
Time frame: From first dose to 12 weeks
Endoscopic Response at Week 12
Endoscopic response will be defined as percentage of participants with a reduction in the total Ulcerative Colitis Endoscopic Index of Severity score. The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) scale: Vascular Pattern: * Normal (score 0) * patchy obliteration (score 1) * Obliterated (score 2) Bleeding * None (score 0) * Mucosal (score 1) * Luminal mild (score 2) * Luminal Moderate or severe (score 3) Erosions and Ulcers * None (score 0) * Erosions ( score 1) * Superficial Ulcer (2) * Deep Ulcer (score 3) A total score represents the following: remission (0-1); mild (2-4); moderate (5-6); and severe (7-8).
Time frame: up to 12 Weeks
Histological Improvement Response Rate at 12 Weeks
Histologic improvement is defined as percentage of participants with a Geboes score of ≤ 3.1 Neutrophils \<5% of crypts, with no crypt destruction, erosions, ulcerations, and granulation tissue. Achieving the following scores for the corresponding grades of the Geboes score: * Score of 0 or 1 for Grade 3 (neutrophils in the epithelium: none or \< 5% crypts involved), and * Score of 0 for Grade 4 (crypt destruction: none), and * Score of 0 Grade 5 (erosion or ulceration: no erosions, ulcerations, or granulation tissue) grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher score indicates more severe disease
Time frame: up to 12 Weeks
| Milestone | Treatment | Placebo |
|---|---|---|
| Started | 88 | 43 |
| Completed | 30 | 12 |
| Not completed | 58 | 31 |
| Withdrew: Other reasons | 5 | 5 |
| Withdrew: Adverse event | 22 | 11 |
| Withdrew: Lack of efficacy | 8 | 7 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 1 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Withdrawal by subject | 18 | 6 |
| Withdrew: Randomized but not treated | 1 | 1 |
Clinical remission response rate is the percentage of participants achieving clinical remission, defined as absolute total Mayo Score and absolute Mayo endoscopy, stool frequency, rectal bleeding. Will be calculated using a modified Mayo score with the following: Stool Frequency (SF) sub score ≤ 1, with ≥ 1 point decrease from baseline, and Rectal Bleeding (RB) sub score = 0, and Endoscopic (ES) sub score ≤ 1 (modified, excludes friability) The modified Mayo score (0 to 9 points) is the sum of 3 components: the SF, RB, and ES sub scores Modified Mayo Score: The modified Mayo score is a 9-point scale; a score of 5 to 9 points (inclusive), which is required for randomization, denotes moderate to severe disease (by protocol definition). considered in clinical remission if a Mayo Score of less than or equal to 2 with no individual sub score greater than 1
| Percentage of Participants | Treatment | Placebo |
|---|---|---|
| Clinical Remission Response Rate at Week 12 | 14.8 (7.4 to 22.2) | 16.3 (5.2 to 27.3) |
Clinical response is defined as percentage of participants with a reduction in total Mayo Score and reduction in rectal bleeding subscore Will be defined as the following: A decrease from baseline in the modified Mayo score of ≥ 2 points, and A decrease from baseline in the modified Mayo score ≥ 30%, and A decrease in rectal bleeding(RB) subscore of ≥ 1 point or absolute RB subscore ≤ 1
| Percentage of participants | Treatment | Placebo |
|---|---|---|
| Clinical Response Rate at 12 Weeks | 37.5 (27.4 to 47.6) | 32.6 (18.6 to 46.6) |
Endoscopic response will be defined as percentage of participants with a reduction in the total Ulcerative Colitis Endoscopic Index of Severity score. The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) scale: Vascular Pattern: * Normal (score 0) * patchy obliteration (score 1) * Obliterated (score 2) Bleeding * None (score 0) * Mucosal (score 1) * Luminal mild (score 2) * Luminal Moderate or severe (score 3) Erosions and Ulcers * None (score 0) * Erosions ( score 1) * Superficial Ulcer (2) * Deep Ulcer (score 3) A total score represents the following: remission (0-1); mild (2-4); moderate (5-6); and severe (7-8).
| Percentage of Participants | Treatment | Placebo |
|---|---|---|
| Endoscopic Response at Week 12 | 19.3 (11.1 to 27.6) | 27.9 (14.5 to 41.3) |
Histologic improvement is defined as percentage of participants with a Geboes score of ≤ 3.1 Neutrophils \<5% of crypts, with no crypt destruction, erosions, ulcerations, and granulation tissue. Achieving the following scores for the corresponding grades of the Geboes score: * Score of 0 or 1 for Grade 3 (neutrophils in the epithelium: none or \< 5% crypts involved), and * Score of 0 for Grade 4 (crypt destruction: none), and * Score of 0 Grade 5 (erosion or ulceration: no erosions, ulcerations, or granulation tissue) grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher score indicates more severe disease
| Percentage of Participants | Treatment | Placebo |
|---|---|---|
| Histological Improvement Response Rate at 12 Weeks | 21.6 (13.0 to 30.2) | 16.3 (5.2 to 27.3) |
Collected over Adverse Events and Serious Adverse Events: (From first dose to last dose + 100 days): Approximately 104 Weeks All-Cause mortality (From randomization to end of study): Approximately 104 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment | 2/87 (2.3%) | 19/87 (21.8%) | 64/87 (73.6%) |
| Placebo | 0/10 (0%) | 2/10 (20%) | 6/10 (60%) |
| BMS-986165 6mg BID During OL Period After Receiving Placebo in Induction Period | 0/32 (0%) | 4/32 (12.5%) | 22/32 (68.8%) |
| Event | Treatment | Placebo | BMS-986165 6mg BID During OL Period After Receiving Placebo in Induction Period |
|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 3/87 | 1/10 | 2/32 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/87 | 1/10 | 0/32 |
| COVID-19 pneumoniaInfections and infestations | 8/87 | 0/10 | 0/32 |
| Congenital aural fistulaCongenital, familial and genetic disorders | 0/87 | 0/10 | 1/32 |
| Enterocolitis infectiousInfections and infestations | 0/87 | 0/10 | 1/32 |
| AnaemiaBlood and lymphatic system disorders | 1/87 | 0/10 | 0/32 |
| Abdominal painGastrointestinal disorders | 1/87 | 0/10 | 0/32 |
| ConstipationGastrointestinal disorders | 1/87 | 0/10 | 0/32 |
| Impaired gastric emptyingGastrointestinal disorders | 1/87 | 0/10 | 0/32 |
| Anal abscessInfections and infestations | 1/87 | 0/10 | 0/32 |
| Event | Treatment | Placebo | BMS-986165 6mg BID During OL Period After Receiving Placebo in Induction Period |
|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 17/87 | 2/10 | 8/32 |
| COVID-19Infections and infestations | 13/87 | 0/10 | 6/32 |
| PyrexiaGeneral disorders | 3/87 | 0/10 | 5/32 |
| RashSkin and subcutaneous tissue disorders | 13/87 | 0/10 | 3/32 |
| NasopharyngitisInfections and infestations | 6/87 | 0/10 | 4/32 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/87 | 0/10 | 4/32 |
| AcneSkin and subcutaneous tissue disorders | 9/87 | 0/10 | 2/32 |
| AnaemiaBlood and lymphatic system disorders | 4/87 | 1/10 | 2/32 |
| Abdominal distensionGastrointestinal disorders | 0/87 | 1/10 | 0/32 |
| Aphthous ulcerGastrointestinal disorders | 5/87 | 1/10 | 2/32 |
| Age, Continuous(Years) | Treatment | Placebo | Total |
|---|---|---|---|
| Mean | 41.6 ± 14.81 | 40.3 ± 13.91 | 41.2 ± 14.48 |
| Sex: Female, Male(Participants) | Treatment | Placebo | Total |
|---|---|---|---|
| Female | 40 | 14 | 54 |
| Male | 48 | 29 | 77 |
| Ethnicity (NIH/OMB)(Participants) | Treatment | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 |
| Not Hispanic or Latino | 83 | 41 | 124 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Treatment | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 7 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 2 | 7 |
| White | 80 | 34 | 114 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Showing the first 100 of 107 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2019 to primary completion in Jun 2021, 23 months.
Results were first posted in Jul 2022, 1 year after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 23 months is below that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib